Ra-SBRT Is Potential Immune Adjuvant for Innate Immune Cell Populations in Advance Stage NSCLC Patients . J. Anal. Oncol. 2019, 8, 71-76. https://doi.org/10.30683/1927-7229.2019.08.10.